207 research outputs found
"Phonathon: Who Gives? Who Gives More?"
Julie M. Ripper is the former Director of Annual Fund at Drake University, and can be contacted at [email protected]. Steve Krantz, Ph.D., is an Associate Professor in the School of Nursing at the University of Missouri in Kansas City. Terri Deems is an Adjunct Faculty member in the School of Education at Drake University.Because of the necessity for fundrasiers to solicit constituents in order to raise the most
funds as effectively as possible, this research takes a look at the phonathon program at a Drake
University, a small Midwestern University. The purpose of this study was to identify the
predictors for the probability of securing a gift and the gift size in response to a call.
Five core recommendations were made to improve the efficiency of the phonathon
program. Future research is needed to determine whether these findings remain true over time or
how these results compare to other fundraising methods
Australian consumer attitudes to health claim - food product compatibility for functional foods
This study with Australian consumers investigated how appealing different health claims combined with particular food carriers were to Australian consumers, and compared the results of a similar study with Dutch consumers. 149 shoppers considered up to 30 different food concepts, rating how ‘attractive’, ‘believable’, and ‘new and different’ they found each concept and their ‘intention to try’. Each variable was significantly related to intention to try (p\u3c0.001) and together explained 56% of the intention score. Claims and carriers independently had a significant effect on ratings of attractiveness and intention to try but, unlike the Dutch study, the carrier was a more important predictor of intention to purchase than the claim. Implications for regulation of health claims for food are discussed
Gender, Sexual Orientation, Ethnicity and Socioeconomic Factors Influence How Wildland Firefighters Communicate their Work Experiences
As Climates Change, Natural Resource Professionals Are Often Working on the Frontlines of Intensifying Environmental Disasters, Acting in Both Scientific and Emergency Response Roles. One Subset of This Group, Wildland Firefighters Often Engage in Multifaceted Careers that Incorporate Elements of Resource Planning, Conservation Management, Community Disaster Relief, and Operational Management. Despite These STEM Roles and Nearly Half (48%) of Them Having Earned at Least a bachelor\u27s degree, usually in a STEM Field, Wildland Firefighters Are Almost Exclusively Lumped with Emergency Responders in the Scientific Literature. We Surveyed 708 Wildland Firefighters with 9 Open Response Questions as Part of a Larger Survey Asking About Experiences and Attitudes in the United States Federal Workplace. from their Responses and Voluntarily Provided Demographic Data, We Extracted Information About Response Length, Use of Hedges, Tag Questions and Imperatives, Use of Personal Language, Use of Expletives and Derogatory Language, Use of Apologetic Language, and the Types of Responses Provided. We Then Analyzed Whether Certain Demographic and Socioeconomic Factors Were Statistical Predictors of Language Use in Wildland Firefighter Survey Responses with the Goal of Ultimately Providing a Framework for Differentiating and Identifying Factors that May Influence Employee Retention, Attitudes, Morale, and Experiences among Wildland Firefighter Sub-Demographics. We Found that Different Demographic Groups Varied in their Responses to Questions: Minority Groups Used Fewer Words and Were More Likely to Relate Personal Experiences Than Majority Groups
Gibberellin and abscisic acid transporters facilitate endodermal suberin formation in Arabidopsis
The plant hormone gibberellin (GA) regulates multiple developmental processes. It accumulates in the root elongating endodermis, but how it moves into this cell file and the significance of this accumulation are unclear. Here we identify three NITRATE TRANSPORTER1/PEPTIDE TRANSPORTER (NPF) transporters required for GA and abscisic acid (ABA) translocation. We demonstrate that NPF2.14 is a subcellular GA/ABA transporter, presumably the first to be identified in plants, facilitating GA and ABA accumulation in the root endodermis to regulate suberization. Further, NPF2.12 and NPF2.13, closely related proteins, are plasma membrane-localized GA and ABA importers that facilitate shoot-to-root GA translocation, regulating endodermal hormone accumulation. This work reveals that GA is required for root suberization and that GA and ABA can act non-antagonistically. We demonstrate how the clade of transporters mediates hormone flow with cell-file-specific vacuolar storage at the phloem unloading zone, and slow release of hormone to induce suberin formation in the maturation zone
Improved precision on the experimental E0 decay branching ratio of the Hoyle state
Stellar carbon synthesis occurs exclusively via the process, in
which three particles fuse to form C in the excited Hoyle
state, followed by electromagnetic decay to the ground state. The Hoyle state
is above the threshold, and the rate of stellar carbon production
depends on the radiative width of this state. The radiative width cannot be
measured directly, and must instead be deduced by combining three separately
measured quantities. One of these quantities is the decay branching ratio
of the Hoyle state, and the current \% uncertainty on the radiative width
stems mainly from the uncertainty on this ratio. The branching ratio was
deduced from a series of pair conversion measurements of the and
transitions depopulating the Hoyle state and state in C,
respectively. The excited states were populated by the C
reaction at 10.5 MeV beam energy, and the pairs were detected with the
electron-positron pair spectrometer, Super-e, at the Australian National
University. The deduced branching ratio required knowledge of the proton
population of the two states, as well as the alignment of the state in
the reaction. For this purpose, proton scattering and -ray angular
distribution experiments were also performed. An branching ratio of
was deduced in the current work,
and an adopted value of is
recommended based on a weighted average of previous literature values and the
new result. The new recommended value for the branching ratio is about 14%
larger than the previous adopted value of
, while the uncertainty has been
reduced from 9% to 5%.Comment: Accepted for publication as a Regular Article in Phys. Rev. C on July
29 202
Long-term follow-up and treatment of congenital alveolar proteinosis
<p>Abstract</p> <p>Background</p> <p>Clinical presentation, diagnosis, management and outcome of molecularly defined congenital pulmonary alveolar proteinosis (PAP) due to mutations in the GM-CSF receptor are not well known.</p> <p>Case presentation</p> <p>A 2 1/2 years old girl was diagnosed as having alveolar proteinosis. Whole lung lavages were performed with a new catheter balloon technique, feasible in small sized airways. Because of some interstitial inflammation in the lung biopsy and to further improve the condition, empirical therapy with systemic steroids and azathioprin, and inhaled and subcutaneous GMCSF, were used. Based on clinical measures, total protein and lipid recovered by whole lung lavages, all these treatments were without benefit. Conversely, severe respiratory viral infections and an invasive aspergillosis with aspergilloma formation occurred. Recently the novel homozygous stop mutation p.Ser25X of the GMCSF receptor alpha chain was identified in the patient. This mutation leads to a lack of functional GMCSF receptor and a reduced response to GMCSF stimulation of CD11b expression of mononuclear cells of the patient. Subsequently a very intense treatment with monthly lavages was initiated, resulting for the first time in complete resolution of partial respiratory insufficiency and a significant improvement of the overall somato-psychosocial condition of the child.</p> <p>Conclusions</p> <p>The long term management from early childhood into young adolescence of severe alveolar proteinosis due to GMCSF receptor deficiency requires a dedicated specialized team to perform technically demanding whole lung lavages and cope with complications.</p
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study
Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay.
Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100.
Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays.
Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study
Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100.
Results:
A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays.
Conclusions:
In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed
- …